Kenzie Midgette Davis
Primary Care · Greenville, NCNPI 1578136859
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 387 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 387 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$937
- Amgen$777
- AbbVie$759
- Axsome Therapeutics, Inc.$397
- GSK$391
- AstraZeneca$391
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,007100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 68 | $937 |
| Amgen | 70 | $777 |
| AbbVie | 52 | $759 |
| Axsome Therapeutics, Inc. | 15 | $397 |
| GSK | 25 | $391 |
| AstraZeneca | 21 | $391 |
| Novartis | 24 | $346 |
| Pfizer | 13 | $195 |
| Lilly USA, LLC | 11 | $189 |
| Boehringer Ingelheim | 10 | $188 |
| Boston Scientific | 5 | $177 |
| Esperion Therapeutics, Inc. | 6 | $110 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $109 |
| Amarin Pharma, Inc. | 6 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $93 |
| Merck | 7 | $92 |
| Astellas Pharma US Inc | 4 | $91 |
| Bayer | 4 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $62 |
| Kowa Pharmaceuticals America, Inc. | 4 | $56 |
| Idorsia Pharmaceuticals US Inc | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Verity Pharmaceuticals Inc. | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Acerus Pharmaceuticals Corporation | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Dexcom, Inc. | 2 | $30 |
| Averitas Pharma Inc. | 1 | $29 |
| Corium, LLC | 1 | $25 |
| Abbott | 1 | $24 |
| Tolmar, Inc. | 1 | $21 |
| Insulet Corporation | 1 | $21 |
| Lundbeck LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,014 in reported general payments places this provider in the 95th percentile of 236 primary care providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 83 | $66,627 |
| JardianceEmpagliflozin | 38 | $43,583 |
| MounjaroTirzepatide | 37 | $39,313 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $31,114 |
| OzempicSemaglutide | 29 | $26,257 |
| Repatha SureclickEvolocumab | 27 | $18,087 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $16,930 |
| SynjardyEmpagliflozin/Metformin Hcl | 13 | $16,209 |
| EntrestoSacubitril/Valsartan | 23 | $16,181 |
| JanuviaSitagliptin Phosphate | 27 | $15,807 |
| TrulicityDulaglutide | 16 | $14,933 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $11,620 |
| EliquisApixaban | 18 | $11,537 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,789 |
| Rosuvastatin Calcium | 202 | $2,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $188 | $76,72364 claims |
| AstraZenecaFarxiga | $391 | $66,62783 claims |
| Lilly USA, LLCMounjaro, Trulicity | $189 | $54,24653 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $391 | $35,90260 claims |
| Novo NordiskOzempic | $937 | $26,25729 claims |
| NovartisEntresto | $346 | $16,18123 claims |
| MerckJanuvia | $92 | $15,80727 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $62 | $11,62014 claims |
| PfizerEliquis | $195 | $11,53718 claims |
| AbbVieSynthroid | $759 | $1,30019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 236 primary care providers in North Carolina.
Other primary care in Greenville
- Bradley JonesGreenville$4K
- Brianna JonesGreenville$2K
- Jessica AllynRaleigh$21K
- Jennifer RogersWinston Salem$17K
- Elizabeth WaltersChapel Hill$14K
- Ragan JohnsonChapel Hill$13K
- Kirkland DickeyPine Hall$11K
- Kimberly WeaverHickory$9K
- Amanda StoneWilmington$9K
- Elizabeth WalshGreensboro$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.